†These authors contributed equally.
Academic Editor: Elena Levantini
Primary bone cancers are rare malignant diseases with significant morbidity and mortality. The treatment regimen relies on a combination of surgery (often involving amputation), chemotherapy and radiotherapy with outcomes dependent on localization of the tumour, grade, size and response to chemotherapy. Both treatment options and survival statistics have remained constant over the past 40 years and alternative therapies need to be explored. Purinergic signalling involving the interaction of extracellular nucleotides with P2 receptors has been investigated in numerous cancers with activation or inhibition a topic of debate. To assess whether purinergic signalling could be a viable target in primary bone cancer a systematic review for relevant primary literature published in PubMed, MEDLINE and Web of Science was performed. Search terms were formulated around three separate distinct topics; expression of P2 receptors in primary bone cancer models, P2 receptor signalling pathways involved and the functional consequences of P2 receptor signalling. Searching identified 30 primary articles after screening and eligibility assessments. This review highlights the diverse expression, signalling pathways and functional roles associated with different P2 receptors in primary bone cancers and provides a systematic summary of which P2 receptors are exciting targets to treat primary bone cancer and its associated symptoms.
Primary bone cancer (PBC) refers to a heterogeneous group of distinct neoplasms
affecting the skeleton arising directly in the bone [1]. They are comprised
predominantly of osteosarcoma (OS), Ewing’s sarcoma, chondrosarcoma and chordoma
[2]. OS is the most common major subtype and is a malignant tumour mainly
affecting children and young adults in the long bones of the extremities with two
peak incidences between 10–19 [3] and
A potential novel therapeutic strategy is targeting purinergic signalling.
Purinergic signalling involves the action of extracellular nucleotides such as
ATP, ADP, UTP and UDP acting on P2 receptors [17], which are subdivided into P2Y
and P2X subtypes [18]. There are eight P2Y receptor family members, which are all
G protein coupled receptors with 7 hydrophobic transmembrane domains with three
extracellular and three intracellular loops, an extracellular N terminus and
intracellular C terminus [19]. These are then further subdivided based on their
sequence and receptor G protein coupling, P2RY1, P2RY2, P2RY4, P2RY6 and P2RY11
couple to G
Purinergic receptors are present on a variety of malignant cells [23] and have displayed both pro-tumour and anti-tumour effects dependent on the cancer type and receptor expressed. Furthermore, studies have identified ATP to be at a high concentration in the tumour microenvironment yet low in surrounding healthy tissue [24]. This may be particularly the case in the bone tumour microenvironment where mechanical loading can stimulate ATP release from osteoblasts [25, 26]. The aim of this review is to examine the evidence for P2 receptor expression in PBC, the downstream signalling pathways associated with P2 receptor activation and the functional consequences. The role of P2 receptors in PBC is summarised in this review, identifying the most promising avenues such as P2RX3 targeting for primary bone cancer induced pain (PBCP) and targeting P2RX4/P2RX7 on the primary tumour as a therapeutic option.
This systematic review follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [27]. Articles published prior to December 10th, 2021 were searched in MEDLINE via OVID, PubMed, and the Web of Science core collection. Three searches were performed, one for each of the key topics within this systematic review; expression of P2 receptors in PBC, downstream signalling pathways associated with P2 activation and the functional consequences of P2 signalling. The extensive list of key search terms/alternative terms can be found in Supplementary Tables 1,2,3.
Eligibility criteria were determined beforehand. This review included only original articles written in English that had used (i) a PBC model and were (ii) investigating a P2 purinergic receptor. Reasons for excluding studies were as follows: (i) reviews, (ii) conference abstracts, (iii) publications in languages other than English, (iv) did not include a PBC model and (v) did not investigate a P2 purinergic receptor.
Articles retrieved from the databases based on the search strategy were screened for duplication, evaluated based on the titles and abstracts, and then finally full texts were read to determine whether or not the eligibility criteria were met. This was done independently by 2 of the authors, (LT and DCG), with the final list of articles to include agreed by all authors.
The risk of bias and quality assessment were adapted from a range of tools including Toxicological data Reliability Assessment Tool (ToxRTool) [28] and the Office of Health Assessment and Translation (OHAT) [29] risk of bias tool with guidance from the Cochrane Handbook [30]. The risk of bias further used SYRCLE’s risk of bias tool [31] and the ARRIVE (Animal research: reporting in vivo experiments) guidelines [32] which were adapted and analysed for selection, performance, detection, attrition, reporting and other biases, characterising each study as low, moderate or high (full criteria Supplementary Table 4). The quality assessment used the Newcastle-Ottawa scale [33] and the National Institutes of Health (NIH) quality assessment tool [34] where a numerical score was generated with 0–3 low, 4–7 moderate and 8–10 high (full criteria Supplementary Table 5). These were performed by both LT and DCG independently, with a final outcome discussed and agreed upon for each individual publication.
A narrative synthesis of included studies was performed to present the results for each key topic. Thematic grouping of studies was performed based on similar outcomes, interventions or comparable populations, using previously published systematic review guidance [35].
Across the three initial searches performed, 1191 articles were retrieved (Search 1 = 376, Search 2 = 299, Search 3 = 516, Supplementary Tables 1,2,3). These articles were manually deduplicated across search databases and across multiple searches, screened for relevancy based on their title and abstracts, and assessed for inclusion and exclusion criteria upon reading the full-length article. Ultimately, 22 papers were included for appraisal. Supplementary manual snowballing [36] and hand-searching [37] were used to find 8 additional studies. In total, 30 studies are included within this systematic review, Fig. 1 summarises the selection process.
PRISMA flow diagram including searching, deduplication, abstract screen, full text reads, excluded articles and final publication N number.
For the risk of bias in vitro and in vivo, selection, performance, detection, attrition, reporting and other bias were assessed for being low, moderate or high for each article. The criteria used to determine the extent of the bias is shown in Supplementary Table 4. For selection and performance bias for in vitro studies, all 26 studies were low [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63], attrition bias was predominantly moderate, with some low [44, 45, 46] and the most poorly performing was reporting bias with 9 studies scoring high [38, 39, 43, 54, 55, 56, 57, 59, 63]. For in vivo studies, performance bias was the lowest [62, 63, 64, 65, 66, 67], attrition and reporting bias were low and moderate apart from one study with high bias for reporting [65]. The most poorly performing areas were selection bias with three scoring high [65, 66, 67] and detection bias which again had three studies scoring high [64, 65, 66]. A full summary of the risk of bias for each study is shown in Table 1 (Ref. [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67]).
Bias Domain | ||||||
In vitro | Selection bias | Performance bias | Detection Bias | Attrition Bias | Reporting Bias | Other bias |
Kumagai et al., 1991 [38] | Low | Low | Low | Low | High | Moderate |
Reimer & Dixon., 1992 [39] | Low | Low | Low | Low | High | Low |
Schofl et al., 1992 [40] | Low | Low | Low | Low | Moderate | Low |
Yu & Ferrier., 1993 [41] | Low | Low | Low | Low | Moderate | Low |
Gallinaro et al., 1995 [42] | Low | Low | Low | Moderate | Moderate | Low |
Kaplan et al., 1995 [43] | Low | Low | Low | Low | High | Low |
Bowler et al., 1995 [44] | Low | Low | Moderate | High | Low | Low |
Urano et al., 1997 [45] | Low | Low | Low | High | Low | Moderate |
Maier et al., 1997 [46] | Low | Low | Low | High | Moderate | Moderate |
Luo et al., 1997 [47] | Low | Low | Low | Low | Low | Low |
Jorgensen et al., 1997 [48] | Low | Low | Moderate | Moderate | Moderate | Low |
Bowler et al., 1998 [49] | Low | Low | Moderate | Moderate | Moderate | Moderate |
Bowler et al., 1999 [50] | Low | Low | Moderate | Low | Low | Low |
Nakamura et al., 2000 [51] | Low | Low | Moderate | Moderate | Moderate | Low |
Buckley et al., 2001 [52] | Low | Low | Moderate | Moderate | Moderate | Low |
Gartland et al., 2001 [53] | Low | Low | Moderate | Low | Moderate | Low |
Katz et al., 2006 [54] | Low | Low | Moderate | Low | High | Low |
Hughes et al., 2007 [55] | Low | Low | Low | Low | High | Low |
D’Andrea et al., 2008 [56] | Low | Low | Low | Low | High | Low |
Alqallaf et al., 2009 [57] | Low | Low | Moderate | Moderate | High | Low |
Liu & Chen., 2010 [58] | Low | Low | Low | Low | Moderate | Low |
Giuliani et al., 2014 [59] | Low | Low | Moderate | Moderate | High | Low |
Qi et al., 2016 [60] | Low | Low | Moderate | Low | Medium | Low |
Wang et al., 2019 [61] | Low | Low | Moderate | Moderate | Low | Low |
Zhang et al., 2019 [62] | Low | Low | Moderate | Moderate | Moderate | Low |
Tattersall et al., 2021 [63] | Low | Low | Moderate | Low | High | Low |
In vivo | ||||||
Gonzales-Rodriguez et al., 2009 [64] | High | Low | High | Low | Low | Low |
Hansen et al., 2011 [65] | High | Low | High | Low | High | Low |
Guedon et al., 2016 [66] | High | Low | Low | Low | Moderate | Low |
Zhang et al., 2019 [62] | Moderate | Low | High | Moderate | Moderate | Low |
He et al., 2020 [67] | Low | Moderate | Low | Low | Moderate | Low |
Tattersall et al., 2021 [63] | Moderate | Low | Low | Moderate | Moderate | Low |
Risk of bias determined for each bias domain-low risk of bias, moderate risk of bias or high risk of bias. |
The quality assessment was performed for both in vitro and in vivo studies, all 30 articles included were peer reviewed. The criteria used to determine the quality of each article is shown in Supplementary Table 5. Although the studies discussed the background and how results were obtained clearly, only 4 explicitly stated an aim [43, 46, 57, 59]. The majority of studies (22 out of 30) clearly stated the cell source, e.g., a previous lab group or commercially bought, and 8 studies did not [40, 41, 44, 45, 48, 53, 61, 62]. Biological and technical repeats were present in 14 in vitro studies [38, 39, 40, 41, 43, 47, 50, 53, 54, 55, 58, 60, 63] with 9 including only information regarding biological [42, 44, 48, 51, 52, 55, 59, 61, 62] and three providing neither [44, 45, 46]. All in vivo studies in this review stated mice N numbers [62, 63, 64, 65, 66, 67].
The quality of the data in each study was assessed for exclusions. For in vitro studies, 16 included ‘data not shown’ [38, 39, 43, 46, 47, 49, 51, 52, 53, 54, 55, 56, 57, 58, 59, 63] and of the 6 in vivo studies three included ‘data not shown’ [63, 65, 66]. For the 26 in vitro studies 14 had representative data [38, 39, 40, 41, 42, 43, 54, 55, 56, 57, 59, 60, 62, 63] and 12 did not specify [44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 58, 61]. For in vivo studies 4 had representative data [62, 63, 65, 67] and two did not specify [64, 66]. The studies were assessed for the statistical analysis performed where 16 in vitro studies stated statistical p values [39, 41, 43, 47, 49, 50, 51, 53, 54, 57, 58, 59, 60, 61, 62, 63] and 10 did not [38, 40, 41, 44, 45, 46, 48, 52, 55, 56]. All 6 in vivo studies stated statistical p values [62, 63, 64, 65, 66, 67]. Finally, the inclusion of limitations and future studies in the discussion was assessed of which 5 in vitro studies [40, 41, 43, 48, 52] and one in vivo study [67] had clear limitations. Future studies were clearly stated in 5 in vitro studies [43, 44, 54, 58, 63] and two in vivo studies [63, 67]. Of the 26 in vitro studies 19 were determined to be of moderate quality [38, 39, 40, 41, 42, 44, 45, 46, 47, 48, 49, 51, 52, 53, 55, 56, 57, 59, 61] and 7 were determined to be high quality [43, 50, 54, 58, 60, 62, 63]. For in vivo studies three were determined to be of moderate quality [62, 64, 65] and three were determined to be high quality [63, 67, 66]. Overall, as no studies were scored low, all studies were determined to be of acceptable quality and included in the review. A summary of the quality assessment for each study can be found in Table 2 (Ref. [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67]).
Study | Quality assessment criteria | ||||||||||
In vitro | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Total |
Kumagai et al., 1991 [38] | Yes | Yes | No | Yes | Yes | No | No | No | Yes | Yes | 6 |
Reimer & Dixon., 1992 [39] | Yes | No | No | Yes | Yes | No | Yes | No | Yes | Yes | 6 |
Schofl et al., 1992 [40] | Yes | No | Yes | Yes | Yes | Yes | No | Yes | No | Yes | 7 |
Yu & Ferrier., 1993 [41] | Yes | No | No | Yes | Yes | Yes | No | Yes | Yes | Yes | 7 |
Gallinaro et al., 1995 [42] | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | Yes | 7 |
Kaplan et al., 1995 [43] | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | 9 |
Bowler et al., 1995 [44] | Yes | No | Yes | Yes | No | Yes | No | Yes | No | Yes | 6 |
Urano et al., 1997 [45] | Yes | No | Yes | Yes | No | Yes | No | No | Yes | Yes | 6 |
Maier et al., 1997 [46] | Yes | Yes | Yes | Yes | No | Yes | No | No | No | Yes | 6 |
Luo et al., 1997 [47] | Yes | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes | 7 |
Jorgensen et al., 1997 [48] | Yes | No | Yes | Yes | No | Yes | No | Yes | Yes | Yes | 7 |
Bowler et al., 1998 [49] | Yes | No | Yes | Yes | No | Yes | Yes | No | No | Yes | 6 |
Bowler et al., 1999 [50] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | No | Yes | 8 |
Nakamura et al., 2000 [51] | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | Yes | 7 |
Buckley et al., 2001 [52] | Yes | Yes | No | Yes | No | Yes | No | Yes | Yes | Yes | 7 |
Gartland et al., 2001 [53] | Yes | No | Yes | Yes | Yes | Yes | Yes | No | No | Yes | 7 |
Katz et al., 2006 [54] | Yes | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes | 8 |
Hughes et al., 2007 [55] | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | 7 |
D’Andrea et al., 2008 [56] | Yes | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | 7 |
Alqallaf et al., 2009 [57] | Yes | Yes | Yes | Yes | No | No | Yes | No | No | Yes | 6 |
Liu & Chen., 2010 [58] | Yes | No | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9 |
Giuliani et al., 2014 [59] | Yes | Yes | Yes | Yes | No | No | Yes | No | No | Yes | 6 |
Qi et al., 2016 [60] | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | 8 |
Wang et al., 2019 [61] | Yes | No | Yes | Yes | No | Yes | Yes | No | No | Yes | 6 |
Zhang et al., 2019 [62] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | 9 |
Tattersall et al., 2021 [63] | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | 9 |
In vivo | |||||||||||
Gonzales-Rodriguez et al., 2009 [64] | Yes | Yes | No | Yes | No | Yes | Yes | No | No | Yes | 7 |
Hansen et al., 2011 [65] | Yes | Yes | No | Yes | No | No | Yes | Yes | No | Yes | 6 |
Guedon et al., 2016 [66] | Yes | Yes | No | Yes | Yes | Yes | Yes | No | Yes | Yes | 8 |
Zhang et al., 2019 [62] | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | Yes | 7 |
He et al., 2020 [67] | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 10 |
Tattersall et al., 2021 [63] | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes | 9 |
Quality Assessment: 0–3 = Low quality, 4–7 = Moderate quality, 8+ = High quality. |
In this review 26 studies perform in vitro investigations using PBC cell lines. These cell lines include UMR106 [38, 39, 41, 42, 43, 47, 48, 50, 52], ROS17/2.8 [40, 43, 48, 54, 55, 56], SaOS-2 [44, 50, 52, 56, 57, 62], U2OS [60, 62], MG-63 [46, 51, 57, 62], TE85 [44, 53, 59, 63], MNNG-HOS [62, 63], HOS unspecified [58], OHS-4 [46], NY [45] and HuO3N1 [45] with two studies investigating a chondrosarcoma cell line- SW1353 [61, 62]. A total of 6 studies performed in vivo investigations of OS-induced mouse models. Two studies use a xenograft model achieved through inoculating BALB/c nude mice with MNNG-HOS [62, 63] and one also used a tail vein injection of MNNG-HOS cells as a lung colonisation model [63]. The other four studies use syngeneic mouse models achieved through inoculating 6-9-week-old C3H/HeJ mice with NCTC 2472 cells [64, 65, 66, 67]. Finally, 5 studies utilised patient tissue samples. Two of those 5 studies included stage IV OS samples [59, 62]. One had 52 samples (39 male and 15 female patients aged 5 to 61) [59] and one had 10 samples (7 male and three female aged 10–50) [62]. The other three studies collected human tissue from GCTB patients [44, 49, 50], with an individual patient being used for each study. Out of these three studies, patient information was disclosed in only one study, where tissue was derived from a 71-year-old male [44]. Of the 30 studies reviewed 6 did not specify which P2 receptor was investigated [38, 39, 40, 41, 42, 55], 12 articles investigated P2Y receptors in vitro; P2RY1 [46, 50, 52, 54, 56], P2RY2 [43, 44, 46, 47, 48, 49, 50, 52, 54, 56, 58], P2RY4 [46, 58], P2RY5 [58], P2RY6 [46], P2RY9 [58], P2RY11 [58, 61], 9 articles investigated P2X receptors in vitro; P2RX4 [51, 57, 58], P2RX5, [51], P2RX6 [45, 51], P2RX7, [51, 54, 57, 58, 59, 60, 62, 63]. One article investigated both P2Y and P2X receptors (P2RX4, P2RX7, P2RY2, P2RY4, P2RY5, P2RY9, P2RY11) [58]. All 6 in vivo studies investigated P2X receptors; P2RX3 [64, 66, 67] P2RX7A [62, 65] P2RX7B [63] and P2RX7K [65].
In this review 26 studies performed in vitro experiments, 10 studies had multiple non-PBC comparators [44, 45, 46, 48, 50, 53, 55, 57, 61], 10 had a single non-PBC comparator [39, 40, 43, 47, 49, 55, 58, 59, 62, 63], and in 7 studies non-PBC comparators were absent [38, 41, 42, 51, 52, 54, 60]. The most common non-PBC comparators were human bone derived osteoblast cells which were included in 5 studies [40, 46, 47, 50, 53], with primary osteoclasts [47], human osteoblast like HOBIT cells [56], MC3T3-E1 murine osteoblasts [43], and human bone marrow mesenchymal stem cells [62] each used in one study. Other sarcoma cell lines were used with both rhabdomyosarcoma (A204, A673, Hs729T, RD) and liposarcoma (SW872) included in one study [45], with human chondrocytes used in the single chondrosarcoma study [61]. Other non-osteoblast cells were used in 12 studies [39, 44, 46, 48, 49, 53, 55, 57, 58, 59, 61, 62]. Of the 6 in vivo studies, 4 had sham non tumour bearing mice comparators [64, 65, 66, 67].
A variety of different experiments were used to confirm P2 receptor expression,
function and signalling. To investigate P2 expression at a molecular level RT-PCR
was used in 10 studies [44, 45, 46, 47, 50, 51, 54, 57, 61, 62], qPCR in three studies
[59, 62, 63], northern blotting in three studies [45, 46, 48], Southern blotting [44]
and in situ hybridisation in one [49]. To determine P2 protein
expression immunohistochemistry (IHC) was used in 5 studies [59, 62, 65, 66, 67],
immunocytochemistry in three [53, 57, 60], western blotting in 4 [57, 61, 62, 67], and
flow cytometry [59] and patch clamping [67] in one study respectively. To
determine receptor functionality 18 studies assessed Ca
To investigate functional consequences of P2 signalling in vitro, 6 studies perform proliferation assays [51, 58, 59, 60, 62, 63], with three assessing cell death [53, 58, 60], two further included migration and invasion [62, 63] and one cell adhesion [63]. Further to this, one included IHC on PBC patient tissue where the level of Ki-67 staining as a marker of cell growth was assessed in samples expressing different P2 receptors [59]. Out of 26 in vitro studies 14 used an antagonist, with suramin being the most commonly used in 6 studies [48, 51, 54, 55, 56, 58], KN62 and pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid (PPADS) in three [51, 62, 57], and A740003 used in three [59, 62, 63], with all other antagonists used once and include other nucleotides for cross reactivity [41], BBG [56], oATP [57], reactive blue 2 [51], NF157 [61] and BBP [58]. A total of 6 studies had in vivo experiments with 4 of them investigating PBCP [64, 65, 66, 67] and two investigating PBC treatment [62, 63]. The 4 that measured pain response as the experimental outcome used mechanical allodynia (using von Frey monofilaments) in three studies [65, 66, 67], thermal hyperalgesia in three studies [64, 65, 67], and limb use and weight bearing assessment in two studies [65, 66]. One study included spontaneous nocifensive behaviours (such as flinching) and tail flick assays [66] and one study included formalin-induced pain and spared nerve injury [65]. Aside from pain behaviour techniques three studies included IHC [65, 66, 67], and one study used micro-CT scanning, histology and an immunoblot [65] in order to determine the different functional effects. For the two in vivo studies examining PBC treatment, the techniques used to determine the functional effects were IHC, micro-CT scanning and histology [62, 63]. All 6 in vivo studies used antagonists, A740003 for PBC treatments [62, 63] and A317491 [64, 67], Anti-P2RX3 antibody [66] and A438079 [65] for PBCP.
Initial studies into P2 receptors in OS did not specify which receptors were
expressed but that it was possible to detect calcium elevation using various P2
receptor agonists. This was the case using the rat OS cell line UMR106 where P2
receptor expression was reported due to a dose dependent Ca
P2 receptor expression within another rat OS cell line (ROS17/2.8) was again
demonstrated by showing Ca
P2 expression has been found in human OS cell lines, one study provides general
evidence for P2 activity in SaOS-2 cells, without assigning activity to either
P2Y or P2X subtypes [40]. Three further studies focus on P2Y expression in SaOS-2
cells with each confirming P2Y receptor activity. P2RY1 was implicated as the
main P2Y subtype [56] although this was not characterised at a molecular level
and was based on Ca
Eight studies have investigated P2X signalling across a wider range of human PBC
cell lines with a predominant focus on P2RX7. Early work demonstrated both
expression and function of this receptor in MG-63 cells by RT-PCR, qRT-PCR,
western blot, immunofluorescence, pore formation and Ca
Finally, two studies show P2 expression in the SW1353 chondrosarcoma cell line, this cell line expresses P2RX7 at the mRNA and protein levels shown by qRT-PCR and western blotting [62], although functionality of this receptor in these cells has not yet been explored. This was the same for P2RY11 in SW1353 cells which had mRNA expression using RT-PCR and protein expression using western blotting but no further functional studies [61]. There is no expression data regarding any P2 receptors in either Ewing’s sarcoma or chordoma. A full summary of P2 expression in vitro for all studies is shown in Table 3 (Ref. [38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63]).
P2 expression in cell lines | |||||||
Study | PBC model | mRNA detection | Protein detection | Functional detection | Non-PBC comparator | Antagonist | Main findings |
Kumagai et al., 1991 [38] | UMR106 | None | None | Fluorescent Ca |
None | No | P2 receptors present on UMR106 which are sensitive to ATP, ADP and UTP. |
Reimer & Dixon., 1992 [39] | UMR106 | None | None | Fluorescent Ca |
Platelets | No | P2 receptors present which are sensitive to ATP, 2-MeSATP, ADP and UTP. |
Schofl et al., 1992 [40] | ROS17/2.8, SaOS-2 | None | None | Fluorescent Ca |
Primary osteoblasts | No | P2 receptors present on SaOS-2 cells which are sensitive to ATP. No response with ROS17/2.8. |
Yu & Ferrier., 1993 [41] | UMR106 | None | None | Fluorescent Ca |
None | Yes-other nucleotides | P2 receptors present on cells which respond to ATP, 2-MesATP and UTP. |
Gallinaro et al., 1995 [42] | UMR106 | None | None | Fluorescent Ca |
None | No | P2 receptors present which respond to ATP, 2-MeSATP, ADP and UTP. |
Kaplan et al., 1995 [43] | UMR106 | None | None | Fluorescent Ca |
MC3T3-El mouse osteoblast cell line | No | P2RY2 receptors present which respond to ATP and UTP. |
Bowler et al., 1995 [44] | SaOS-2, TE85 | RT-PCR* | None | None | Macrophage, primary human bone derived cells | No | SaOS-2 and TE85 express P2RY2 at the mRNA level. |
Southern blotting* | |||||||
Urano et al., 1997 [45] | NY and HuO3N1 | Northern Blot * | None | None | Rhabdomyosarcoma: A204, A673, Hs729T, RD & liposarcoma: SW872 | No | P2RX6R transcript present in NY and HuO3N1. |
RT-PCR * | |||||||
Maier et al., 1997 [46] | MG-63 | Northern Blot * | None | None | SK-N-SH, U138 and H4 Y79, U87, CI-215 118-INI- Brain-derived cell lines. Primary human bone sample | No | P2RY1, P2RY2, P2RY4, P2RY6 |
RT-PCR $ | expressed in MG-63 and OHS-4 cells. | ||||||
Luo et al., 1997 [47] | UMR106 | None | None | Fluorescent Ca |
Primary osteoclasts | No | Cells respond to ATP and UTP suggesting P2RY2 expression. |
Jorgensen et al., 1997 [48] | UMR106 | Northern Blot* | None | Fluorescent Ca |
Hamster tracheal epithelia cells, mouse macrophage like cell line J774 | Yes-suramin | P2RY2 expressed at the mRNA level in UMR106 but not ROS17/2.8. |
ROS17/2.8 | |||||||
Bowler et al., 1999 [50] | SaOS-2 UMR106 | RT-PCR* | None | Fluorescent Ca |
2 populations of Primary human bone derived cells | No | P2RY1 has higher expression than P2RY2 in SaOS-2 cells. |
Nakamura et al., 2000 [51] | MG-63 | RT-PCR\̂hfil None | Fluorescent Ca |
None | Yes-suramin, reactive blue 2, PPADS | MG-63 cells express P2RX4, P2RX5, P2RX6 and P2RX7 but not P2RX1, P2RX2, or P2RX3. | |
Buckley et al., 2001 [52] | UMR106 | None | None | Fluorescent Ca |
None | No | P2Y1R expressed in UMR106 cells. |
Gartland et al., 2001 [53] | SaOS-2, TE85 | RT-PCR* | IHC | Ethidium bromide uptake | Primary human bone derived cells, THP-1 cells | Yes-PPADS | SaOS-2 cells express PR2X7 at the mRNA and protein levels. TE85 expresses P2RX7 mRNA but not protein. |
Katz et al., 2006 [54] | ROS17/2.8 | None | None | Fluorescent Ca |
None | Yes-suramin | P2RY1 and P2RY2 receptor are present sensitive to ATP, ADP and UTP. |
Hughes et al., 2007 [55] | ROS17/2.8 | None | None | Fluorescent Ca |
COS7 (Kidney fibroblast like) HEK-239 | Yes-suramin | ROS17/2.8 not responsive to UTP or ATP. |
D’Andrea et al., 2008 [56] | ROS17/2.8, SaOS-2 | None | None | Fluorescent Ca |
HOBIT Human osteoblast like | Yes-suramin | SaOS-2 cells are sensitive to ATP, ADP and UTP. ROS17/2.8 are not. |
Alqallaf et al., 2009 [57] | SaOS-2, MG-63 | RT-PCR* | Western Blot immunofluorescence | YO-PRO1 uptake | BON1 (Human Pancreatic), HEK-293+P2RX7 | Yes-BBG, KN-62, oATP and PPADS | Both cell lines express P2RX4 and P2RX7 at the mRNA and protein levels, P2RX2 was absent in both cell lines. |
Liu & Chen., 2010 [58] | HOS | RT-PCR # | None | Fluorescent Ca |
PC12- Rat pheochromocytoma cell line | Yes-suramin, BBP | HOS cells express P2RX4, P2RX7, P2RY2, P2RY4, P2RY5, P2RY9 and P2RY11 at the mRNA level. |
Giuliani et al., 2014 [59] | TE85 | RT-PCR* | IHC | Ethidium bromide uptake | HEK293+P2RX7 | Yes-A740003 | P2RX7 not endogenously expressed in TE85 cells but were transfected with P2RX7A and P2RX7B splice isoforms. |
Flow cytometry | |||||||
Qi et al., 2016 [60] | U2OS | None | Immunofluorescence | Lucifer yellow and calcein uptake | None | Yes-KN62 | U2OS cells express P2RX7 at the protein level. |
Wang et al., 2019 [61] | SW1353 | RT-PCR* | Western Blot | None | Huh-7 human hepatocellular carcinoma, Human chondrocytes | Yes- NF157 | SW1353 cells express P2RY11 at the mRNA and protein level. |
Zhang et al., 2019 [62] | SaOS-2, U2OS, MNNG-HOS, MG-63, SW1353 | qRT-PCR* | Western Blot | None | Human bone marrow mesenchymal stem cells | Yes-A740003 | P2RX7 is expressed by all cell lines at the mRNA and protein levels. Expression is highest in MNNG-HOS and lowest in SaOS-2. |
Tattersall et al., 2021 [63] | TE85, MNNG-HOS | RT-PCR, qRTPCR* | None | Fluorescent Ca |
HEK-293+P2RX7A | Yes-A740003 | P2RX7 not endogenously expressed in TE85 and MNNG-HOS cells but were transfected with P2RX7B splice isoform. |
* Specific receptor only; ^ All P2X; $ All P2Y; # All P2X and P2. |
Four studies investigating PBCP targeted P2RX3 and P2RX7 in NCTC2472 mouse models through receptor inhibition. One study inhibited P2RX3 with anti-P2RX3 antibody using IP injection 7 days after cell inoculation and every 5 days thereafter. Although this study showed P2RX3 was detected (using IHC) in the L2 dorsal root ganglia that innervate the tumour-bearing femur, there was no focus on demonstrating expression on the primary bone tumour [66]. This was a similar case in another study where P2RX3 was targeted using A317498 administered as a peritumoral injection 30 minutes before observation of mouse pain behaviours, although again no techniques were used to explicitly show expression of P2RX3 in the primary tumour [64]. A final study investigated P2RX3 trafficking in PBCP, P2RX3 was targeted by A317498 administered a week after cell inoculation by intrathecal injection daily, assessment of P2RX3 was performed on L3-L5 Dorsal root ganglion (DRG) neurons. P2RX3 protein was confirmed in the neurons using western blotting and immunofluorescence with its function shown using patch clamp recordings [67] but again had no analysis of the primary tumour was performed. These studies show that targeting P2RX3 for PBCP is through modification of the bone tumour microenvironment/the pain response pathways and not the tumour itself as this hasn’t been assessed. Aside from P2RX3 targeting for PBCP, P2RX7 and its role in pain has also been examined in one study. OS bearing P2RX7 knock out (KO) mice were susceptible to PBCP and had an earlier onset of pain-related behaviours compared with cancer-bearing wild-type mice. Treatment with A438079 (administered subcutaneously on various different days depending on which pain behaviour was been assessed) did not alleviate pain related behaviours in models of PBCP. When analysing the mice, the KO mice were identified as having P2RX7 mRNA expression in spinal cord tissue but not in osteoclasts; western and immunoblotting were then used to confirm protein expression although this was not determined for different isoforms, and the study did not focus on P2RX7 expression on the primary tumour itself [65]. Only two studies target the P2RX7 (full length and P2RX7B) expressed on the PBC tumour as a potential therapeutic option by treating MNNG-HOS OS cells with the P2RX7 agonist BzATP [62] and antagonist A740003 [62, 63]. P2RX7 expression and function was confirmed on the cells (detailed in 3.6.2 in vitro section) before the intra-tibia, paratibial and tail vein injection [62, 63]. The effect of targeting any P2 receptors either as a direct tumour target or to control PBCP in Ewing’s sarcoma, chondrosarcoma or chordoma using in vivo models has not been demonstrated. A full summary of P2 expression in vivo for all studies is shown in Table 4 (Ref. [62, 63, 64, 65, 66, 67]).
P2 expression in vivo | |||||||
Study | PBC model | mRNA detection | Protein detection | Functional detection | Non-PBC comparator | Antagonist | Main findings |
Gonzales-Rodriguez et al., 2009 [64] | Syngeneic mouse | None | None | PBCP- thermal hyperalgesia. | Sham mice | Yes-A317491 | P2RX3 expression not explicitly explored besides assessment of bone pain behaviour. |
NCTC 2472 | |||||||
Hansen et al., 2011 [65] | Syngeneic mouse | None | IHC | PBCP- thermal hyperalgesia, mechanical allodynia, spared nerve injury, formalin-induced pain, limb use and weight bearing. | Sham mice | Yes-A438079 | P2RX7A and P2RX7K identified in spinal cord tissue. A438079 did not reduce PBCP. |
NCTC 2472 | IHC, micro-CT, histology, immunoblot. | ||||||
Guedon et al., 2016 [66] | Syngeneic mouse | None | IHC | PBCP- mechanical allodynia limb use and weight bearing, tail flick assay, spontaneous nocifensive behaviours such as flinching. IHC. | Sham mice | Yes-Anti-P2RX3 antibody | P2RX3 expressed in the L2 dorsal root ganglia that innervate the tumour-bearing femur. |
NCTC 2472 | |||||||
Zhang et al., 2019 [62] | Xenograft mouse | None | None | IHC, micro-CT and histology. | None | Yes-A740003 | P2RX7 shown to be present and functional on the cells before injection, expression not explicitly explored ex vivo. However IHC, micro-CT and histology assessed P2RX7 effects on the tumour, bone and lung metastasis. |
MNNG-HOS | |||||||
He et al., 2020 [67] | Syngeneic mouse | None | Patch clamp, Immunofluorescence, western blot | PBCP- thermal hyperalgesia, mechanical allodynia. IHC. | Sham mice | Yes-A317491 | P2RX3 protein was confirmed L3-L5 DRG neurons. |
NCTC 2472 | |||||||
Tattersall et al., 2021 [63] | Xenograft mouse | None | None | IHC, micro-CT and histology. | None | Yes-A740003 | P2RX7B transfected into the cells before injection, expression not explicitly explored ex vivo. However IHC, micro-CT and histology assessed P2RX7B effects on the tumour, bone and lung metastasis. |
MNNG-HOS+P2RX7B | |||||||
Tail vein MNNG-HOS+P2RX7B |
Three studies identify P2RY1 and P2RY2 in GCTB. The first identified P2RY2 mRNA using RT-PCR and Southern blotting in tissue from a single patient [44]. The second identified P2RY2 transcript localisation in the osteoclast population of a tumour surgically removed from a patient using in situ hybridisation, but although the transcript was detected it was found absent on the surface of the primary cells as a functioning receptor [49]. In the final study, along with P2RY2, P2RY1 expression was shown in a GCTB tumour again by RT-PCR but did not include further functional experiments [50]. No other P2Y receptors have been analysed in other PBC patient samples.
Two studies show P2RX7 expression in samples derived from OS patients [59, 62]. The first screened a panel of 54 stage IV OS samples for expression of either P2RX7A or P2RX7B splice isoforms using IHC. These differ due to the lack of a C-terminal tail on the P2RX7B, meaning separate antibodies can be used to target the N-terminal region detecting both P2RX7A and P2RX7B, whereas antibodies directed to the C-terminal region will only be present when the full length receptor P2RX7A is present, and therefore this can distinguish between the two. These isoforms were expressed in 81% of tumour samples [59] whilst a subsequent study also using stage IV OS samples (n = 10) found P2RX7 expression to be highly expressed when compared to normal bone samples from patients having a hip replacement [62]. None of the studies identified have examined any other P2X receptors in OS or other PBCs. A full summery of P2 expression in clinical samples for all studies is shown in Table 5 (Ref. [44, 49, 50, 59, 62]).
P2 expression in patient tissue | |||||||
Study | PBC model | mRNA detection | Protein detection | Functional detection | Non-PBC comparator | Antagonist | Main findings |
Bowler et al., 1995 [44] | GCTB (n = 1) | RT-PCR * | None | None | Normal bone tissue | No | P2RY2 expressed in GCTB. |
Bowler et al., 1998 [49] | GCTB (n = 1) | In situ hybridization * | None | Ca |
None | No | P2RY2 expressed in the osteoclast population of GCTB. |
Bowler et al., 1999 [50] | GCTB (n = 1) | RT-PCR* | None | None | Primary human bone derived cells | No | P2RY1 expressed in GTCB. |
Giuliani et al., 2014 [59] | OS Stage IV (n = 54) | None | IHC | None | None | Yes-A740003 | P2RX7A and P2RX7B expressed in 81% of samples. |
Zhang et al., 2019 [62] | OS Stage IV (n = 10) | None | IHC | None | Normal bone tissue | Yes-A740003 | P2RX7 is highly expressed in 10 OS samples when compared to 2 normal bone samples from patients having hip replacements. |
* Specific receptor only; ^ All P2X; $ All P2Y; # All P2X and P2Y. |
3.6.5.1 Modulation of P2-mediated Ca
Five studies describe the ability of other non-nucleotide molecules to modulate
Ca
One study investigated H
The final study used an array of phthalates to show their ability to suppress
ATP-mediated Ca
Ca | |||||
Study | PBC model | Non-PBC comparator or control | Therapeutic intervention (agonist or antagonist) | Pathway detection techniques | Main findings |
Kaplan et al., 1995 [43] | UMR106 | MC3T3-El mouse osteoblast cell line, vehicle treated cells. | 100 |
Fluorescent Ca |
PTH potentiates ATP or UTP-mediated Ca |
Bowler et al., 1999 [50] | SaOS-2 | Primary HBDCs, vehicle control. | 10 |
Fluorescent Ca |
PTH does not potentiate ATP or UTP-mediated Ca |
Buckley et al., 2001 [52] | UMR106 | No cell comparator, vehicle control. | 0.1 to 100 |
Fluorescent Ca |
PTH potentiates ADP-mediated Ca |
D’Andrea et al., 2008 [56] | SaOS-2, ROS17/2.8 | HOBIT, vehicle control. | 1 to 100 |
Fluorescent Ca |
H |
Liu & Chen., 2010 [58] | HOS | PC12, data presented as percentage of untreated control response. | 1 to 1000 |
Fluorescent Ca |
Phthalates supresses Ca |
Upregulated signalling pathways | |||||
Bowler et al., 1999 [50] | SaOS-2 | Primary HBDCs, vehicle control. | 10 |
Northern blotting, Luciferase reporter gene assay | c-fos is induced when PTHr and P2 signalling are activated. |
UMR106 | 100 ng/mL PTH | ||||
Buckley et al., 2001 [52] | UMR106 | No cell comparator, vehicle control. | 0.1 to 100 |
Luciferase reporter gene assay | c-fos is induced when PTHr and P2 signalling are activated. |
100 ng/mL PTH | |||||
Giuliani et al., 2014 [59] | TE85 | Jurkat cells, vehicle and untreated control. | 50 |
NFATc1 activation assay (ELISA-based) | NFATc1 transcription factor activation in response to BzATP activation of P2RX7. |
10 | |||||
Zhang et al., 2019 [62] | MNNG-HOS | Human BMSCs; untreated control; vector control. | 5 to 125 |
WB, ELISA | BzATP-mediated P2RX7 activates Pi3K/Akt, mTOR/HIFa/VEGF and Wnt pathways. |
5 | |||||
Lentiviral infection | |||||
Tattersall et al., 2021 [63] | TE85, MNNG-HOS | Untransfected cells, HEK-293. | 10 |
RNA-seq | A740003 treatment downregulated FN1/LOX/PDGFB/IGFBP3/BMP4 in P2RX7B transfected MNNG-HOS cells. |
P2 receptors downstream of other signalling | |||||
He et al., 2020 [67] | Syngeneic mouse | Sham mice. | A317491 (20 mg/10 |
WB, ELISA | P2RX3 can be upregulated by Wnt5b/Ryk. |
NCTC 2472 | anti-Ryk (50 ng/10 | ||||
Wnt5b (50 ng/mL) |
3.6.5.2 Modulation of Gene Pathways in PBC
Two studies describe P2Y-mediated c-fos induction [50, 52], with both
using luciferase-based reporters to assess the induction of c-fos
promoter elements. In UMR106 cells elevated Ca
Three further studies identify downstream signalling pathways associated with
P2RX7. Firstly in TE85 OS cells transfected with P2RX7, Nuclear factor of
activated T cells complex 1 (NFATc1) which is dependent upon intracellular
Ca
3.6.6.1 Effects of P2 Receptors on Proliferation in PBC
Five studies show that P2X receptors can play a role in proliferation. When
stimulated with 100
P2RX7 and its splice variants have been shown to affect proliferation [59, 62, 63]. Transfection of TE85 with the full length P2RX7A, P2RX7B or
cotransfection of P2RX7A and P2RX7B all provided a strong growth increase
compared to control TE85 cells over a 72-hour period. Additionally after 24
hours, treatment with 100
In a further study, MNNG-HOS and SaOS-2 cell proliferation was detected using a
CCK-8 assay over a 72-hour period [62]. When stimulated with 5, 25 or 125
3.6.6.2 Effects of P2 Receptors on Mineralisation in PBC
Only one study associates P2 activity with bone mineralisation, this was assessed over a 21 day period by Alizarin red staining in TE85 OS cells. Transfection of P2RX7A, P2RX7B and both isoforms together in cells confers differing effects. The P2RX7A did not affect bone mineralisation, P2RX7B reduced mineralisation and P2RX7A and P2RX7B together increased mineralisation. This was attributed to differences in spontaneous ATP release and ability to form a pore. Typically, P2RX7A form pores whilst P2RX7B lacks the pore forming c-terminal, however in Te85 cells expression of both P2RX7A and P2RX7B together was required to induce pore formation, potentially due to the isoforms co-associating on the membrane [59]. Due to the pore forming ability of P2RX7A and P2RX7B together, there is greater spontaneous ATP release which can drive mineralisation. This is important as OS patients often present with large amounts of ectopic mineralised bone, and this suggests that P2RX7 isoform expression can contribute towards this phenotype. Furthermore, the cells expressing the P2RX7B isoform alone which lacks the pore formation ability is suggestive of an undifferentiated state compared to cells expressing both variants that allow for pore formation. This, therefore, can inform on the aggressiveness of the cancer and help identify which patients may benefit from targeting P2RX7 [59].
3.6.6.3 Effects of P2 Receptors on Cytotoxicity in PBC
Three studies demonstrate an anti-tumour effect associated with P2 receptors.
The first evidence for the direct involvement of P2RX7 in eliciting cytotoxic
effects was in SaOS-2 cells [53]. BzATP treatment resulted in lactate
dehydrogenase (LDH) release and membrane blebbing characteristic of apoptosis,
this was further confirmed with TUNEL staining. Pre-treatment with the P2X
antagonist PPADS prevented the blebbing and reduced TUNEL staining to levels
comparable to untreated controls [53]. It was then further shown by using an MTT
assay that ATP at
3.6.6.4 Effects of P2 Receptors on Metastasis in PBC
Two studies showed that P2RX7 and its splice variants are involved in metastasis [62, 63]. In vitro wound-healing, transwell invasion [62, 63] and cell adhesion [63] assays were used to show the involvement of P2RX7 and P2RX7B signalling in the migration and invasion of MNNG-HOS, TE85 [62, 63] and SaOS-2 cells [62]. Full length P2RX7 or the truncated P2RX7B both provided a strong increase in migration, invasion and decreased cell adhesion. As with increased proliferation, these cell behaviours are dependent upon the PI3K/Akt pathway where activation of P2RX7 is further associated with epithelial-to-mesenchymal transition (EMT), whereby E-cadherin is diminished at the mRNA and protein levels whilst EMT markers such as vimentin, fibronectin and SNAIL are elevated [62]. When targeting the P2RX7 in vivo, mice treated with BzATP showed a greater number of metastatic nodules in the lung when compared to the controls, which could be reduced in mice treated with A740003 [62]. Further to this P2RX7B transfected MNNG-HOS cells tended to have increased lung metastasis in both a xenograft and tail vein models [63].
3.6.6.5 Effects of P2 Receptors on PBC Pain
Three studies demonstrate the involvement of P2RX3 in PBCP [64, 66, 67]. Firstly it was shown in vivo that A317491 reduced OS-induced thermal hyperalgesia [64] and that anti-P2RX3 antibody treated mice showed reduced skin hypersensitisation associated with PBCP, but did not have improvements in the overall skeletal pain behaviours [66]. Further to this P2RX3 was upregulated in the DRG neurons in the bone-tumour microenvironment by Wnt5b acting through CaMKII in bone tumour bearing mice, this upregulation resulted in increased thermal hyperalgesia and PBCP, which was reduced with A317491 [67]. The only other P2 receptor assessed for its role in PBCP is the P2RX7. It was demonstrated that P2RX7 KO mice had PBCP behaviours with a more severe phenotype and earlier onset compared with wild-type tumour bearing mice [65].
The role for purinergic signalling involving both P2Y and P2X receptors in the tumour microenvironment and their contribution towards the pathogenesis of many cancers is now acknowledged due to the growing evidence from in vitro and in vivo studies, and have promising therapeutic implications. The aim of this systematic review was to assess the role of P2 receptors specifically in PBC relating to subtype expression, associated signalling pathways and the functional consequences associated with each individual receptor (summarised in Fig. 2). The majority of papers included in this systematic review focus on OS cells however, many of the early studies use these cells as a replacement for osteoblasts to investigate purinergic signalling in normal bone physiology. This is a huge drawback causing a lack of focus on OS as a disease state, with some observed effects not being attributed to OS but to osteoblast behaviour with no particular focus truly on PBC. A further criticism is that OS cell lines can provide different models when cultured or used in mice and can be of murine or human origin, the human cell lines would have more relevant translatable biology relating to P2 receptors. SaOS-2 cells are largely characteristic of mature osteoblasts. The MG-63 population comprise cells with both mature and immature osteoblastic features and U2OS cells are described as osteoblastic whilst sharing fibroblastic features [68]. MNNG-HOS cells are derived from TE85 cells and form tumours in mice which produce a phenotype with large amounts of ectopic bone [69] which represents clinical OS but demonstrate very little metastasis [69, 70]. In some instances, the exact receptor profiles within certain cell lines has been disputed, this can be partially accredited to differences in methodology, but also there is the possibility for long term culture to alter cell phenotype. A shift towards the use of tissue from PBC patients would be beneficial as only a minimal number of studies used PBC tissue with low sample sizes. This review also includes in vivo experiments utilising human xenograft and syngeneic murine models. The use of syngeneic models gives the added benefit of an intact immune system however a xenograft uses human cells [62, 63, 64, 65, 66, 67], patient-derived xenograft (PDX) models could be used as an alternative which would provide the most relevant model to study P2 receptor biology in PBC due to their physiologically relevant tumour microenvironment, heterogeneity and natural tumour progression.
Schematic representation of P2Y and P2X expression, signalling and function in PBC and the potential PBC outcomes that could be influenced and targeted.
Early studies within this systematic review focussed on P2Y receptors and
historically these were detected first. Molecular characterisation was not
provided in some studies and therefore they depended on Ca
Evidence relevant to P2RY11 in PBC showed that this receptor was expressed at
both mRNA and protein level in SW1353 chondrosarcoma cells [61] and
inhibition of P2RY11 using NF157 resulted in reduced expression of
TNF-
In summary, P2YR expression in PBC remains relatively underexplored and represented a gap in knowledge, given that some P2Y targeted treatments (such as the P2RY12 antagonist Clopidogrel) have achieved significant successful clinical use for other conditions [78] targeting them in a PBC context may be beneficial.
Several studies included within this systematic review focus on P2RX7 in OS with
expression and function described in multiple cell lines in vitro,
in vivo and in clinical patient samples. Evidence from this review
suggests a pro-tumour role for P2RX7 in OS mediated by its ion channel, and
therefore its inhibition could be of therapeutic value, whilst its pore
activation could also induce cell death. The dual nature of P2RX7 in OS is still
being established. High levels of P2RX7 was demonstrated in patient samples
[59, 62] and this could be expanded by linking disease characteristics such as
stage or presence of metastasis in order to identify specific cohorts of eligible
patients that may be suitable for P2RX7 targeted treatments. Further to this,
P2RX7 activation has been associated with signalling pathways such as NFATc1
[59], Pi3K/Akt, Wnt and mTOR/HIF1
PBCP is a debilitating symptom associated with PBC, evidence from this systematic review demonstrates that pharmacological inhibition of P2RX3 in OS using A317491 or anti P2RX3 antibody in vivo is a potential therapeutic for pain reduction [64, 66, 67] acting within the bone-tumour microenvironment. This is important as managing PBCP would be beneficial to PBC patients when approaching their treatment regimen. The role of P2RX3 in cancer pain has previously been described [87] and ATP in the tumour microenvironment can potentially activate nociceptive nerve endings responsible for the pain response, therefore, inhibition may be beneficial [87]. Further to this P2RX3 inhibitors are now approved for human use where Gefapixant is used clinically for chronic cough [88] and therefore drugs that target P2RX3 are available for repurposing. Aside from its role in pain, P2RX3 has not been explored regarding its effect on the primary tumour itself, or in any other PBC type such as Ewing’s sarcoma or chondrosarcoma and could be a possible target, and further studies are therefore warranted to elucidate the therapeutic potential of P2RX3 in PBCs.
PBC is a rare and complex disease with high levels of heterogeneity and therefore there has been a lack of new therapeutics developed, this review aimed to systematically highlight progress in the purinergic field concerning which P2 receptors could potentially play a role in PBC progression or associated symptoms and which could provide suitable targets. Based on the evidence in this systematic review, there is a lack of progress in P2Y receptor characterisation and function in OS, aside from early studies. The most promising therapeutic targets we believe are P2X receptors including P2RX3 for PBCP and P2RX4/P2RX7 for targeting the primary tumour, as these have been shown to contribute towards important OS outcomes in vitro and in vivo such as growth and metastasis. It may be the case that only certain cohorts of patients would benefit from this approach based on the individuals’ expression profile of specific receptors or their isoforms. Therefore, future therapeutic strategies will benefit from a comprehensive characterisation and association of P2 receptors with clinical outcomes of patients with PBC.
AG designed the research study, LT, DCG, VLT, KMS, NBAL performed the research, LT, DCG, analysed the data, LT, DCG, AG wrote the manuscript. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript.
Not applicable.
Thanks to all the peer reviewers for their opinions and suggestions.
This research received no external funding.
The authors declare no conflict of interest.